The research house said the pharmaceutical company
PETALING JAYA: Hovid Bhd posted a core net loss of RM300,000 for the financial year ended June 30, 2017, missing CIMB Equities Research and Bloomberg consensus expectations of a core net profit due to the revocation of the manufacturing licences of two plants earlier this year.
The research house said the pharmaceutical company’s fourth quarter ended June (Q4FY17) revenue fell 12.9% on-quarter to RM35.6mil as the revocation led to manufacturing losses and lower sales volume.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
